Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Earnings for Veracyte, Inc. (VCYT)
Earnings in 2023 (TTM): $-76,612,000
According to Veracyte, Inc.'s latest financial reports the company's current earnings (TTM) are $-76,612,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Veracyte, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-76,612,000 | $-74,404,000 |
| 2022 | $-36,427,000 | $-36,560,000 |
| 2021 | $-81,649,000 | $-75,563,000 |
| 2020 | $-34,909,000 | $-35,847,000 |
| 2019 | $-12,599,000 | $-16,481,000 |
| 2018 | $-22,999,000 | $-22,999,000 |
| 2017 | $-31,003,000 | $-31,003,000 |
| 2016 | $-31,358,000 | $-31,358,000 |
| 2015 | $-33,704,000 | $-33,704,000 |
| 2014 | $-29,373,000 | $-29,373,000 |
| 2013 | $-25,580,000 | $-25,580,000 |
| 2012 | $-18,649,000 | $-18,649,000 |
| 2011 | $-14,445,000 | $-14,445,000 |